Home / Pharmaceutical / Pharmaceutical Market China Q2 2013

Pharmaceutical Market China Q2 2013

Published: Nov 2013 | No Of Pages: 142 | Published By: Kelly Scientific Publications
Pharmaceutical Industry China Q2·2013 – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 196 tables & figures within 142 pages. The Chinese biopharmaceutical market is presented as follows:
 
By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
 
A wealth of financial information is provided including:
 
  • Company financials, sales & revenue figures – historical to Q2·2013
  • China GDP, economic growth, export (bulk drug, formulations) figures
  • Indian health expenditure as a function of GDP
  • Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
  • Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
  • Projected figures of strategic emerging industry GDP percentage contribution 
SWOT, Economic and Business Environment specifics include:
 
  • Key strengths, weaknesses and threats influencing leading player position within the market
  • Top Five Contract Pharmaceutical Export Markets of China
  • Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
  • Multinational penetration into the Chinese Pharma Market
  • Comprehensive product portfolios, R&D activity and pipeline therapeutics
  • M&A activity and future strategies of top Chinese pharmacos
  • Economic indicators, trade policy, merchandise and commercial trade statistics
  • Gross Domestic Product of China, historic and projection analysis
  • Chinese economic outlook in comparison to advanced economies
  • Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
  • Prescription drug sales distribution channels in China
 Major biogeneric products in China
 
This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.
 
  • Amoytop Biotech
  • Active Pharmaceutical Products
  • Beijing Continent Pharmaceuticals
  • FusoGen Pharmaceuticals
  • Shanghai Huaguan Biochip
  • SiBiono GeneTech
  • Abbott
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson Medical
  • Merck
  • Novartis
  • Pfizer
  • Roche
  
Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed.  The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
 
What you will gain:
 
  • An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
  • Current market facts, figures and product lines of key players in the industry
  • An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
  • Knowledge of how the Chinese pharma market will integrate into the global healthcare market
  • Information on key regulatory and government policies
  • Data on levels of private and publically funded biopharma studies in China
  • Strategies on how to adapt and restructure current business models to this industry
 
This report tackles key concerns to the Chinese biopharmaceutical market such as:
 
  • Lack of regulatory policy and legislation
  • Reimbursement schemes and payers concerns
  • Funding and government sponsorship issues
  • International scepticism of Chinese safety and efficacy therapeutic profiles
 
This report will tell you if the companies mentioned are:
 
  • Strong, competitive players
  • Pooling their resources for specific growth and therapeutic areas
  • Investing strategically in R&D
  • Have a history of strategic M&A activity
1.0 Summary 7
1.1 Objectives of Report 7
1.2 Scope of Study 8 
1.3 Data Sources and Methodology 9 
1.4 Key Findings and Observations 9 
1.5 Executive Summary 10 
 
2.0 Chronic Disease Prevalence Statistics 13 
 
3.0 Business Environment 15 
3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics 15 
3.2 Gross Domestic Product of China, Historic and Projection Analysis 17 
3.3 Annual Health Expenditure in China, Historic and Projected Analysis 18 
3.4 Global and Chinese Economic Outlook 2010-2013 19 
3.5 Chinese Economic Outlook in Comparison to Emerging Markets and Developing Countries 20 
3.6 Chinese Economic Outlook in Comparison to Advanced Economies (US, Europe) 22 
 
4.0 Chinese Pharmaceutical Market 27 
4.1 Market Overview 27 
4.2 Main Players in China’s Pharmaceutical Industry 30 
4.3 Anti-Allergy Drug Market 30 
4.4 Asthma Drug Market 31 
4.5 Benign Prostate Hyperplasia Drug Market 31 
4.6 Anti-Depressant Drug market 32 
4.7 Dermatitis Drug Market 34 
4.8 Diabetes Drug Market 35 
4.9 Hypertension Drug Market 36 
4.10 Dyslipidaemia Drug Market 37 
4.11 Senile Dementia Drug Market 38 
4.12 Cancer Drug Market 39 
4.13 Rheumatoid Arthritis Drug Market 39 
4.14 Ophthalmological Drug Market 40 
4.15 Liver Disease Drug Market 42 
4.16 Antibiotic Drug Market 43 
 
5.0 Government and Regulation Environment 44 
5.1 12th Five Year Plan 44 
5.2 Intellectual Property for Pharmaceuticals in China 46 
5.3 State Food and Drug Administration (SFDA) 51 
5.4 Pharmaceutical Distribution Process in China 54 
 
6.0 China – Third Largest Pharma Market 2012 57 
6.1 China – At the Forefront of Emerging Markets 57 
6.2 Generic Medication Market and China 57 
6.3 Novel Product Drug Development 59 
6.4 Drug Development Cost and Outsourcing 61 
6.5 Drug Development Case Study - Beijing Continent Pharmaceuticals 62 
6.6 China’s Pharmaceutical Export Market 62 
6.7 Spot Light - China Medical City Taizhou 64 
 
7.0 Global Pharmaceutical Companies Interest in China 66 
7.1 Abbott China 66 
7.2 AstraZeneca China 71 
7.3 Bayer China 74 
7.4 Boehringer Ingelheim China 76 
7.5 Eli Lilly China 78 
7.6 GlaxoSmithKline China 78 
7.7 Johnson & Johnson Medical China 80 
7.8 Merck China 81 
7.9 Novartis China 83 7.10 Novo Nordisk China 84
7.11 Pfizer China 84
7.11.1 Pfizer China R&D Centre 86 
7.11.2 Pfizer China Products 86 
7.12 Roche China 89 
7.13 Sanofi China 90 
 
8.0 Chinese Pharmaceutical Companies 91 
8.1 Amoytop Biotech 91 
8.2 Active Pharmaceutical Products 92 
8.2.1 Research and Development 92 
8.2.2 Financial Information 92 
8.3 Beijing Continent Pharmaceuticals 93 
8.4 FusoGen Pharmaceuticals 93 
8.4.1 Financial Information 94 
8.5 Shanghai Huaguan Biochip 94 
8.5.1 Financial Information 96 
8.6 SiBiono GeneTech 96 
8.6.1 Financial Information 97 
8.7 Sinovac Biotech 97 
8.7.1 Financial Information 99 
8.7.2 New Products 103 
8.7.3 Split Virion Pandemic Influenza Vaccine 103 
8.7.4 RabEnd 103 
8.7.5 Pipeline Portfolio 103 
8.7.6 EV71 virus Vaccine 103 
8.7.7 Pneumococcal Conjugate Vaccine 104 
8.7.8 Pneumococcal Polysaccharide Vaccine 104 
8.7.9 Varicella Vaccine 104 
8.7.10 Measles, Mumps and Rubella Vaccines 104 
8.7.11 Rotavirus Vaccine 104 
 
9.0 Drivers, Restraints, Challenges and Opportunity Analysis 105 
9.1 Key Drivers of the Pharmaceutical Market in China 105 
9.2 Key Restraints of the Pharmaceutical Market in China 106 
9.3 Challenges of the Pharmaceutical Industry in China 107 
9.4 Opportunities Within BioPharma China 109
Table 2.1: Most Prominent Cancer Manifestations in China 14 
Table 2.2: Top Fifty Diseases in China Today (non-cancer) 14 
Table 2.3: Top Infectious Disease States in China Today 14 
Table 3.1: World Trade Organisation Basic Indicators on China 15 
Table 3.2: World Trade Organisation Trade Policy of China 15 
Table 3.3: World Trade Organisation Merchandise Trade Statistics: China 16 
Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China 16 
Table 3.5: Summary of International Monetary Fund Members’ Quota, Reserve Position, SDR 
Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly 
Historical Transactions of China 17 
Table 3.6: China Statistics 17 
Table 4.1: Top Global Pharma Markets 2003-2013 27 
Table 4.2: Major Players in China’s Anti-Allergy Drug Market 30 
Table 4.3: Major Players in China’s Asthma Drug Market 31 
Table 4.4: Major Players in China’s Benign Prostate Hyperplasia (BPH) Drug Market 32 
Table 4.5: Major Players in China’s Anti-Depressant Drug Market 33 
Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics 34 
Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market 35 
Table 4.8: Major Players in China’s Dermatitis Drug Market 35 
Table 4.9: Major Players in China’s Diabetic Drug Market 36 
Table 4.10: Major Players in China’s Hypertension Drug Market 37 
Table 4.11: Major Players in China’s Dyslipidaemia Drug Market 37 
Table 4.12: Major Players in China’s Senile Dementia Drug Market 38 
Table 4.13: Major Players in China’s Cancer Drug Market 39 
Table 4.14: Major Players in China’s Rheumatoid Arthritis Drug Market 40 
Table 4.15: Major Players in China’s Ophthalmological Drug Market 41 
Table 4.16: Major Players in China’s Liver Disease Drug Market 42 
Table 4.17: Major Players in China’s Antibiotic Drug Market 43 
Table 5.1: Seven Strategic Emerging Industries of China’s 12th
 Five Year Plan 2011-2015 44 
Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual 
Property Strategy, 2012 46 
Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China 54 
Table 5.4: Prescription Drug Sales Distribution Channels in China 54 
Table 6.1: Major Biogeneric Products in China 58 
Table 6.2: Imported Therapeutics with Administrative Protection in China 58 
Table 6.3: Expired Proprietary Pharmaceuticals in China 59 
Table 6.4: Reasons Why Multinational Companies Seek CMO’s in China 61 
Table 6.5: Comparison of Clinical Trial Cost between China and the USA 62 
Table 6.6: Five Functional Districts of China Medical City 64 
Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City 65 
Table 7.1: Top Multinational Company Performance, China 67 
Table 7.2: Abbott Areas of Expertise 68 
Table 7.3: Abbott Key Global Products 71 
Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions 71 
Table 7.5: Abbott China Anaesthesia Product Profile 71 
Table 7.6: Abbott China Cardiovascular Product Profile 71 
Table 7.7: Abbott China Vaccine Product Profile 71 
Table 7.8: Abbott China Digestion Product Profile 72 
Table 7.9: Abbott China HIV Product Profile 72 
Table 7.10: Abbott Rheumatology HIV Product Profile 72 
Table 7.11 Abbott China Gynaecological Product Profile 72 
Table 7.12 Abbott China Urological Product Profile 72 Table 7.13 Abbott China Liver Disease Product Profile 72
Table 7.14 Abbott China Diagnostic Product Profile 73
Table 7.15: Abbott China Molecular Diagnostic Product Profile 74 
Table 7.16: Abbott Blood Glucose Meter Product Profile 74 
Table 7.17: Abbott Cardiovascular Product Profile 74 
Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile 74 
Table 7.19: Important Milestones in AstraZeneca China’s History 75 
Table 7.20: AstraZeneca China Anaesthetic Range of Products 76 
Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products 76 
Table 7.22: AstraZeneca China Gastrointestinal Range of Products 76 
Table 7.23: AstraZeneca China Infection Range of Products 76 
Table 7.24: AstraZeneca China Neurology Range of Products 76 
Table 7.25: AstraZeneca China Oncology Range of Products 76 
Table 7.26: AstraZeneca China Respiratory Range of Products 76 
Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally 2012 78 
Table 7.28: AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally 2010-2012 79 
Table 7.29: Bayer China Important Milestones 83 
Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China 84 
Table 7.31: Bayer - Leading Therapeutics in China 85 
Table 7.32: Bayer Top Selling Consumer Health Products 86 
Table 7.33: Boehringer Ingelheim Major Products in China 86 
Table 7.34: Main Therapeutic Areas of Interest to Boehringer Ingelheim China 87 
Table 7.35: Global Therapeutic Pipeline, Boehringer Ingelheim 87 
Table 7.36: Major Global Boehringer Ingelheim Therapeutic Products 88 
Table 7.37: GlaxoSmithKline Prescription Portfolio and Indications in China 90 
Table 7.38: GlaxoSmithKline Vaccine Portfolio and Indications in China 91 
Table 7.39: GlaxoSmithKline Over the Counter Portfolio and Indications in China 91 
Table 7.40: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, 2012 92 
Table 7.41: GlaxoSmithKline Global Vaccine Sales 2012 93 
Table 7.42: Significant Milestones in Johnson and Johnson China History 95 
Table 7.43: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area 
and Percentage Change, 2012 97 
Table 7.44: Merck Serono Pharmaceutical Key Therapeutic Areas in China 99 
Table 7.45: Merck Serono Fertility and Infertility Therapeutic Portfolio in China 99 
Table 7.46: Merck Serono Therapeutic Portfolio in China 99 
Table 7.47: Merck Pharmaceutical Hong Kong Therapeutic Portfolio 100 
Table 7.48: Range of Diabetic Products from Novo Nordisk China 104 
Table 7.49: QUICKFACTs - Pfizer China 106 
Table 7.50: Important Milestones – Pfizer China 106 
Table 7.51: Pfizer China – Range of Infectious Disease Therapeutics for Chinese Health Care Market 108 
Table 7.52: Pfizer China – Range of Mental Health Products for Chinese Health Care Market 108 
Table 7.53: Pfizer China – Range of Genitourinary Products for Chinese Health Care Market 108 
Table 7.54: Pfizer China – Range of Endocrine Products for Chinese Health Care Market 108 
Table 7.55: Pfizer China – Range of Women’s Health Products for Chinese Health Care Market 108 
Table 7.56: Pfizer China – Range of Cardiovascular Disease Products for Chinese Health Care Market 109 
Table 7.57: Pfizer China – Range of Oncology Products for Chinese Health Care Market 109 
Table 7.58: Pfizer – Key Consumer Healthcare Global Products 109 
Table 7.59: Pfizer – Key Speciality Care Global Products 109 
Table 7.60: Pfizer – Key Oncology Global Products 109 
Table 7.61: Pfizer – Key Global Established Products 110 
Table 7.62: Pfizer – Key Innovative Products in Emerging Markets 110 
Table 7.63: Pfizer – Key Animal Health Global Products 110 
Table 7.64: Pfizer Product Sales with Significant Impact on Revenues 2011:2012 Comparison 110 
Table 7.65: Roche Pharmaceuticals Product List in China 112 Table 7.66: Roche Global Sales (CHF Millions) by Therapeutic Area, 2011, 2012 and Percentage 
Change (CER) 113
Table 7.67: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South 
Korea, Turkey, 2011, 2012 and Percentage Change (CER) 115 
Table 7.68: Seven Growth Platforms of Sanofi China 116 
Table 7.69: Key Therapeutic Areas of Sanofi China 117 
Table 8.1: Important Milestones in Amoytop Biotech’s Development 120 
Table 8.2: Amoytop Biotech – Main Objectives of Research and Development Division 121 
Table 8.3: Amoytop Biotech – Panel of Recombinant Protein Therapeutics in Clinical Studies 121 
Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant 
Protein Therapeutics within Clinical Investigation in China 122 
Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech 122 
Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech 122 
Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals 125 
Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals 125 
Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio 126 
Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile 126 
Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio 126 
Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio 126 
Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio 127 
Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech 128 
Table 8.15: Gendicine - Potential Oncology Indications for Future Approval 129 
Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech 130 
Table 8.17: Important Milestones in the History of Sinovac Biotech 130 
Table 8.18: Pipeline Portfolio of Sinovac Biotech 130 
Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012 132 
Table 9.1: Key Drivers of the Pharmaceutical Market in China 138 
Table 9.2: Key Restraints of the Pharmaceutical Market in China 139 
Table 9.3: Key Challenges of the Pharmaceutical Market in China 140 
Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020 140 
Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China 142 
Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages 13 
Figure 3.1: China GDP Figures 2006-2015 18 
Figure 3.2: Annual Health Expenditure in China 2006-2015 18 
Figure 3.3: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013 19 
Figure 3.4: Global, Emerging Market & Developing Countries & China Economic Growth Change 
2010-2013 20 
Figure 3.5: Global, Emerging Market & Developing Countries & Russia Economic Growth Change 
2010-2013 21 
Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 
2010-2013 21 
Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 
2010-2013 22 
Figure 3.8: Global, US and Germany Economic Growth 2010-2013 23 
Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017 23 
Figure 3.10: Global, France and Italy Economic Growth 2010-2013 24 
Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017 24 
Figure 3.12: Global, UK and Spain Economic Growth 2010-2013 25 
Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013 25 
Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017 26 
Figure 4.1: The Chinese Healthcare Industry by Sector, 2011 29 
Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution 2011-2020 45 
Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for 
Imported Drugs 52 
Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for 
Clinical Trials 53 
Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution 
Market 55 
Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution 
Market 55 
Figure 6.1: Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth 57 
Figure 6.2: Number of Investigational New Drug Applications in China 2003-2010 59 
Figure 6.3: Number of New Drug Applications in China 2003-2010 60 
Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in 
China 60 
Figure 6.5: Percentage of Clinical Trial Drug by Disease State 60 
Figure 6.6: China’s Regional Pharmaceutical Processing Trade Export Market Share Percentage 63 
Figure 6.7: Contract Amount of China’s Regional Pharmaceutical Processing Trade Export 63 
Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China 64 
Figure 7.1: Abbott Laboratories Geographic Distribution of Revenue –USA, Established and 
Emerging Markets 68 
Figure 7.2: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015 69 
Figure 7.3: Abbott – Business Specialization Strategy 2012: Diversified Medical Products and 
Research-Based Pharmaceuticals 69 
Figure 7.4: Abbott Diversified Medical Product Portfolio 70 
Figure 7.5: AstraZeneca Sales Revenue (US$ Millions) in China, 2010-2012 77 
Figure 7.6: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Western Europe, 
Emerging Markets 2012 78 
Figure 7.7: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global Sales 
2010-2012 79 
Figure 7.8: AstraZeneca Gastrointestinal Product (Nexium) Global Sales 2010-2012 80 
Figure 7.9: AstraZeneca Infection Product (Synagis) Global Sales 2010-2012 80 
Figure 7.10: AstraZeneca Neuroscience Product (Seroquel-IR, -XR) Global Sales 2010-2012 80 
Figure 7.11: AstraZeneca Oncology Product (Zoladex) Global Sales 2010-2012 81 Figure 7.12: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales 
2010-2012 82
Figure 7.13: Boehringer Ingelheim Oncology Compounds in Development 88 
Figure 7.14: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales 
2012 (£ Billions) 92 
Figure 7.15: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, 2012 93 
Figure 7.16: GlaxoSmithKline Global Vaccine Sales by Therapeutic Area, 2012 94 
Figure 7.17: GlaxoSmithKline Global Sales by Geographic Region – USA, Europe, Emerging 
Markets, Japan, 2012 94 
Figure 7.18: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area, 
2012 98 
Figure 7.19: Novartis International Sales (%) by Geographic Region, 2012 102 
Figure 7.20: Novartis International Sales (US$ Millions) by Geographic Region, 2012 102 
Figure 7.21: Novo Nordsk Total Diabetes Care Market Sales Performance (DKK Millions) China 
2010-2012 105 
Figure 7.22: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, 
Modern Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China 2010-2012 105 
Figure 7.23: Business Sectors – Pfizer China 107 
Figure 7.24: Roche Total Global Sales (CHF Millions) 2011, 2012 114 
Figure 7.25: Roche Global Sales (CHF Millions) by Therapeutic Area, 2011, 2012 114 
Figure 7.26: Roche Pharmaceutical Division Emerging Market Total Sales 2011, 2012 115 
Figure 7.27: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South 
Korea, Turkey, 2011, 2012 116 
Figure 7.28: Sanofi Geographic Market Share (%) – Emerging Markets, USA and Western Europe 
2012 118 
Figure 7.29: Sanofi Geographic Market Share (%) –China, Russia and USA 2012 118 
Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression 124 
Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service 127 
Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012 132 
Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012 133 
Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012 133 
Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012 134 
Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012 135 
Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011 1
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +